TabletsClinical Overview
Metformin Hydrochloride and Glimepiride is a cornerstone dual-action antidiabetic combination on the WHO Model List of Essential Medicines. Metformin acts as an insulin-sensitizing biguanide that reduces excessive hepatic glucose output and improves peripheral glucose uptake without causing hypoglycemia or weight gain, while glimepiride acts as an insulin secretagogue, binding to SUR1 receptors on pancreatic beta-cell membranes to stimulate physiological postprandial insulin release. Indicated as an adjunct to diet and exercise in type 2 diabetes mellitus inadequately controlled by metformin alone.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally once daily with breakfast or the first main meal of the day with water. Swallow sustained-release tablets whole without chewing or crushing. Always consume a carbohydrate-containing meal after taking this medicine to avoid hypoglycemia.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Hypoglycemia (hunger, sweating, tremor, dizziness), nausea, diarrhea, abdominal discomfort, metallic taste, headache. Rare/Severe: Boxed warning: Lactic acidosis (rare but fatal metformin accumulation); severe prolonged hypoglycemia, hemolytic anemia in G6PD deficiency, and cholestatic jaundice.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Black box warning: Lactic acidosis; risk increases with renal impairment, sepsis, and excessive alcohol. Contraindicated in severe renal impairment (eGFR < 30 mL/min), acute metabolic acidosis, and diabetic ketoacidosis. Educate patients on recognizing and treating hypoglycemia (carry glucose tablets or candy).
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered endocrinologist, diabetologist, or qualified physician before initiating, adjusting dosages of, or substituting any antidiabetic or hormonal medication.
Metformin Hydrochloride Prolonged-release 500mg + Glimepiride 2mg Tablets
Metformin Hydrochloride and Glimepiride is a cornerstone dual-action antidiabetic combination on the WHO Model List of Essential Medicines. Metformin acts as an insulin-sensitizing biguanide that reduces excessive hepatic glucose output and improves peripheral glucose uptake without causing hypoglycemia or weight gain, while glimepiride acts as an insulin secretagogue, binding to SUR1 receptors on pancreatic beta-cell membranes to stimulate physiological postprandial insulin release. Indicated as an adjunct to diet and exercise in type 2 diabetes mellitus inadequately controlled by metformin alone.
Glimepiride Tablets 1mg
Glimepiride is a potent, third-generation oral sulfonylurea on the WHO Model List of Essential Medicines. It binds to the 65 kDa subunit of the sulfonylurea receptor (SUR1) on pancreatic beta-cell membranes, closing ATP-sensitive potassium channels, depolarizing the cell membrane, opening voltage-dependent calcium channels, and triggering exocytosis of pre-formed insulin granules. Exhibits rapid association and dissociation kinetics, resulting in physiologic insulin secretion with relatively lower risk of prolonged hypoglycemia compared to older sulfonylureas. Indicated as an adjunct to diet and exercise in type 2 diabetes mellitus.
Glimepiride Tablets 2mg
Glimepiride is a potent, third-generation oral sulfonylurea on the WHO Model List of Essential Medicines. It binds to the 65 kDa subunit of the sulfonylurea receptor (SUR1) on pancreatic beta-cell membranes, closing ATP-sensitive potassium channels, depolarizing the cell membrane, opening voltage-dependent calcium channels, and triggering exocytosis of pre-formed insulin granules. Exhibits rapid association and dissociation kinetics, resulting in physiologic insulin secretion with relatively lower risk of prolonged hypoglycemia compared to older sulfonylureas. Indicated as an adjunct to diet and exercise in type 2 diabetes mellitus.
Metformin Hydrochloride Sustained Release Tablets 1000 mg
Metformin Hydrochloride is the foundational first-line biguanide oral antihyperglycemic agent on the WHO Model List of Essential Medicines. It activates AMP-activated protein kinase (AMPK) in the liver, suppressing mitochondrial respiratory chain complex I, thereby potently inhibiting hepatic gluconeogenesis and glycogenolysis, while stimulating peripheral glucose uptake into skeletal muscle and delaying intestinal glucose absorption. Does not stimulate beta-cell insulin secretion, having zero intrinsic hypoglycemia risk and promoting weight neutrality or mild weight loss. Indicated as the initial pharmacological drug of choice for type 2 diabetes mellitus in adults and children aged 10 and older, and off-label in polycystic ovary syndrome (PCOS).